<DOC>
	<DOCNO>NCT02364297</DOCNO>
	<brief_summary>In last year , important advance do treatment prevention fundal variceal bleed patient cirrhosis . Experts agree combination pharmacological endoscopic therapy ( tissue adhesive ) first line therapy acute bleed episode isolate gastric varix ( IGV1 ) type 2 gastroesophageal varix ( GOV2 ) varix ; whereas transjugular intrahepatic portosystemic shunt ( TIPS ) consider rescue therapy . TIPS show effectively prevent variceal rebleeding potential increase incidence hepatic encephalopathy and/or liver failure . In sense , recent randomize control trial ( RCT ) esophageal variceal bleeding show early TIPS , perform first 72h patient admission result significant decrease failure control bleed early late rebleeding . Moreover , survival also significantly increase well portal-hypertension related complication ( ascites , spontaneous bacterial peritonitis , hepatorenal syndrome , etc ) . The present study direct compare outcome patient acute bleed fundal varix ( IGV1 GOV2 ) treat standard therapy ( vasoactive drug + endoscopic injection tissue adhesive ) without early TIPS ( perform first 1-5 day admission ) . Main end-point survival free variceal rebleeding 1 year inclusion .</brief_summary>
	<brief_title>TIPS Fundal Variceal Bleeding ( TFB Study )</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<criteria>Patients develop acute variceal bleed GOV2 and/or IGV1 define accord Baveno II criterion , admit Hospital receive standard combine medical therapy ( somatostatin 3 mg/12h continuous IV infusion terlipressin , 2mg/4h IV + endoscopic injection tissue adhesives per center protocol ) . Hepatocarcinoma without therapeutic option ( accord Milan criterion ) . Portal mesenteric vein thrombosis avoid performance TIPS . Acute alcoholic hepatitis . Platelet count &lt; 20.000/mm3 . Previous treatment portosystemic shunt . Pregnancy . Previous inclusion current study . Terminal liver disease ( bilirrubin &gt; 10 mg/dL and/or prothrombin index &lt; 30 % ) ; fatal nonliver disease . Denied informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bleeding gastric varix</keyword>
	<keyword>Transjugular intrahepatic portosystemic shunt ( TIPS )</keyword>
	<keyword>Injection adhesive</keyword>
</DOC>